Home Tags NaPi2b

Tag: NaPi2b

ESMO 2020: Updated Interim Data of XMT-1536 Supports Continued Development in...

Updated interim phase I date for the safety, tolerability, and efficacy porting for the ovarian cancer cohort of an ongoing expansion study evaluating XMT-1536...

ESMO 2020: XMT-1536 Shows 34% ORR in Phase I Expansion Study...

Updated interim safety, tolerability, and efficacy data for the ovarian cancer cohort of the ongoing expansion portion of the Phase I study evaluating XMT-1536...

Mersana Reports Updated Data from the XMT-1536 Phase I Dose Escalation...

Mersana Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet...

Mersana Therapeutics Initiates Expansion Study of XMT-1536 in Platinum-Resistant Ovarian Cancer...

XMT-1536 is a first-in-class antibody-drug conjugate (ADC) targeting the sodium-dependent phosphate transport protein (NaPi2b) using the Dolaflexin platform developed by Mersana Therapeutics, a clinical-stage...

Lifastuzumab Vedotin is Well-tolerated + Improves Objective Response Rate in Phase...

Lifastuzumab vedotin, also known as DNIB0600A (RO5541081) and RG-7599, is an antibody-drug conjugate or ADC.In clinical trials the investigational drug is compared to pegylated...

FDA Clears Mersana’s IND Application for XMT-1536

Focusing on discovering and developing a pipeline of novel antibody-drug conjugates or ADCs based on its proprietary Dolaflexin® platform, Mersana Therapeutics' Investigational New Drug...

Preclinical Data Supports the Development of XMT-1536 in a Broad Population...

Update data from preclinical studies with XMT-1536, an antibody-drug conjugates or ADC being developed by Mersana Therapeutics targeting NaPi2b, were presented in a poster...